MedinCell S.A
Medincell is dedicated to creating innovative therapeutic solutions with a focus on global health. They develop a portfolio of advanced treatments, leveraging their proprietary BEPO® technology platform to produce long-acting injectable medications. Collaborating with major pharmaceutical companies and foundations, Medincell aims to make their treatments widely accessible and to redefine standards of care worldwide.
Industries
Nr. of Employees
medium (51-250)
Patents
Long acting injectable formulation comprising risperidone and biodegradable polymers
US-12329851-B2
View DetailsMethod for morselizing and/or targeting pharmaceutically active principles to synovial tissue
US-11865205-B2
View Details
Long acting injectable formulation comprising risperidone and biodegradable polymers
US-12329851-B2
View DetailsMethod for morselizing and/or targeting pharmaceutically active principles to synovial tissue
US-11865205-B2
View DetailsProducts
Long‑acting subcutaneous risperidone formulation (monthly or bimonthly)
An extended‑release subcutaneous risperidone formulation administered monthly or every two months for relapse prevention in schizophrenia; delivered in a prefilled syringe and distributed via a commercial partner in the US.
Monthly subcutaneous olanzapine long‑acting formulation (Phase 3 candidate)
A monthly subcutaneous long‑acting olanzapine formulation in Phase 3 clinical development for schizophrenia, developed to provide prolonged antipsychotic exposure with a favorable safety profile.
Intra‑articular celecoxib long‑acting formulation for post‑operative pain (Phase 3)
A localized intra‑articular long‑acting formulation of celecoxib administered at knee replacement to reduce post‑operative pain and inflammation, with potential activity up to three months and the goal of reducing opioid use.
Long‑acting subcutaneous risperidone formulation (monthly or bimonthly)
An extended‑release subcutaneous risperidone formulation administered monthly or every two months for relapse prevention in schizophrenia; delivered in a prefilled syringe and distributed via a commercial partner in the US.
Monthly subcutaneous olanzapine long‑acting formulation (Phase 3 candidate)
A monthly subcutaneous long‑acting olanzapine formulation in Phase 3 clinical development for schizophrenia, developed to provide prolonged antipsychotic exposure with a favorable safety profile.
Intra‑articular celecoxib long‑acting formulation for post‑operative pain (Phase 3)
A localized intra‑articular long‑acting formulation of celecoxib administered at knee replacement to reduce post‑operative pain and inflammation, with potential activity up to three months and the goal of reducing opioid use.
Services
Licensing of a sustained‑release injectable delivery platform to pharmaceutical partners and development of collaborative commercialization agreements.
Design and conduct of pivotal clinical studies including Phase 3 execution, patient recruitment and endpoint evaluation in multiple indications.
Preparation and management of regulatory dossiers and interactions with regulatory authorities to support NDA and supplemental filings.
Licensing of a sustained‑release injectable delivery platform to pharmaceutical partners and development of collaborative commercialization agreements.
Design and conduct of pivotal clinical studies including Phase 3 execution, patient recruitment and endpoint evaluation in multiple indications.
Preparation and management of regulatory dossiers and interactions with regulatory authorities to support NDA and supplemental filings.
Expertise Areas
- Long‑acting injectable therapeutics
- Clinical trial management (pivotal Phase 3)
- Formulation and sustained‑release drug delivery
- Regulatory strategy and FDA submissions
Key Technologies
- Depot sustained‑release injectable formulations
- Subcutaneous injectable delivery
- Intra‑articular long‑acting injection
- Prefilled syringe delivery format